论文部分内容阅读
目的观察卵巢恶性肿瘤组织中多药耐药基因的表达及其表达与临床病理因素的关系。方法采用免疫组化技术 (S-P法 )对 40例卵巢恶性肿瘤组织中的 P-糖蛋白 (P-gp)、谷胱甘肽 S-转移酶 (GST-π)、拓扑异构酶 (Topo-II)等多药耐药基因的表达进行检测 ,分析其与病理类型、组织学分级、临床及分期化疗疗效的关系。结果 14 0例卵巢恶性肿瘤中 P-gp、GST-π、Topo-II的阳性表达分别为3 7.5 %、5 5 %、65 % ,其相互间均呈正相关。但三者与临床分期、术前化疗无关。2 2 6例上皮性卵巢恶性肿瘤中 P-gp、GST-π、Topo-II的阳性率分别为 60 %、61.5 %、5 2 .2 % ,其相互间亦呈正相关 ,与病理分化有明显负相关 ,病理分化低其表达阳性率高。 GST-π阳性率与临床分期有正相关关系 (P<0 .0 5 ) ,但 P-gp、Topo-II与临床分期、术前化疗无相关关系。 3 14例非上皮性卵巢恶性肿瘤中 P-gp、GST-π、Topo-II的阳性率分别为 40 %、3 8.5 %、47.8% ,其相互间均有正相关关系 ,但三者与临床分期、术前化疗无相关关系。结论本研究结果表明测定卵巢恶性肿瘤组织中的 P-gp、GST-π、Topo-II,根据其结果对选择化疗用药具有指导意义
Objective To investigate the expression of multidrug resistance gene in ovarian cancer and its relationship with clinicopathological factors. Methods The expression of P-gp, GST-π, Topo-I and P-gp in 40 cases of ovarian cancer were detected by immunohistochemistry (SP method) II) and other multidrug resistance gene expression was detected, and its relationship with the pathological type, histological grade, clinical and staging of chemotherapy. Results The positive expressions of P-gp, GST-π and Topo-II in 14 cases of ovarian cancer were 37.5%, 55% and 65%, respectively, which were positively correlated with each other. However, the three were not associated with clinical stage and preoperative chemotherapy. The positive rates of P-gp, GST-π and Topo-II in 26 cases of epithelial ovarian cancer were 60%, 61.5% and 52.2% respectively, which were also positively correlated with each other and with pathological differentiation Negative correlation, low pathological differentiation of its positive expression rate. There was a positive correlation between the positive rate of GST-π and clinical stage (P <0.05), but P-gp and Topo-II had no correlation with clinical stage and preoperative chemotherapy. The positive rates of P-gp, GST-π and Topo-II in 14 non-epithelial ovarian malignancies were 40%, 38.5% and 47.8%, respectively, but positively correlated with each other Staging, no correlation between preoperative chemotherapy. Conclusion The results of this study show that the determination of P-gp, GST-π, Topo-II in ovarian cancer tissue, according to the results of the selection of chemotherapy drugs have guiding significance